Literature DB >> 22002709

SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas.

Adriana Handra-Luca1, Sylviane Olschwang, Jean-François Fléjou.   

Abstract

The TGFβ signalling pathway is a growth inhibitor system that operates in both normal and tumour cells. Alterations to components of this pathway, including SMAD4, result in resistance to growth inhibition and uncontrolled proliferation. The aim of this study was to analyse the relationships between SMAD4, a key protein in the growth-inhibiting TGFβ pathway; cell proliferation proteins Ki67, p27 and S-phase kinase-associated protein 2 (SKP2); and mismatch repair (MMR) proteins as well as prognostic indicators in colorectal adenocarcinomas. A series of 230 sporadic colorectal adenocarcinomas were studied using tissue microarrays by immunohistochemistry for SMAD4, Ki67, p27, SKP2 and MMR protein (hMLH1, hMSH2 and hMSH6) expression. Protein expression was analysed with respect to pathological prognostic criteria. Loss of SMAD4 nuclear expression (27/230, 12%) correlated with the presence of lymph node metastases, MMR protein expression and the absence of p27 in tumour cells (p = 0.04, p = 0.08 and p = 0.03, respectively). A high Ki67 index did not correlate with SMAD4 expression; however, it did correlate with moderate or poor histological differentiation, SKP2 expression and aberrant or absent MMR protein expression (p = 0.02, p < 0.01 and p < 0.01, respectively). In conclusion, the results of our study suggest that the loss of SMAD4, occurring in 12% of colorectal adenocarcinomas, correlated with the presence of lymph node metastases and absence of p27 expression but not with high cellular proliferation. However, high proliferation correlated with SKP2 and aberrant MMR protein expression. Although the advantage of immunohistochemistry is high throughput, our results allow only an initial evaluation, and subsequent studies, including genetic analyses, are required.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002709     DOI: 10.1007/s00428-011-1152-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  72 in total

1.  Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease.

Authors:  A Maitra; K Molberg; J Albores-Saavedra; G Lindberg
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27.

Authors:  Y Katayose; M Kim; A N Rakkar; Z Li; K H Cowan; P Seth
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

3.  Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Authors:  R E Wilentz; G H Su; J L Dai; A B Sparks; P Argani; T A Sohn; C J Yeo; S E Kern; R H Hruban
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  Frequent 4-bp deletion in exon 9 of the SMAD4/MADH4 gene in familial juvenile polyposis patients.

Authors:  W Friedl; R Kruse; S Uhlhaas; M Stolte; B Schartmann; K M Keller; M Jungck; M Stern; S Loff; W Back; P Propping; D E Jenne
Journal:  Genes Chromosomes Cancer       Date:  1999-08       Impact factor: 5.006

5.  Inactivation of both alleles of the DPC4/SMAD4 gene in advanced colorectal cancers: identification of seven novel somatic mutations in tumors from Japanese patients.

Authors:  M Koyama; M Ito; H Nagai; M Emi; Y Moriyama
Journal:  Mutat Res       Date:  1999-08       Impact factor: 2.433

6.  Effect of DPC4 gene on invasion and metastasis of colorectal carcinoma cells.

Authors:  De-Sheng Xiao; Ji-Fang Wen; Jing-He Li; Kuan-Song Wang; Zhong-Liang Hu; Jian-Hua Zhou; Zheng-Hao Deng; Ying Liu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2006-12       Impact factor: 3.848

7.  Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP.

Authors:  Shuji Ogino; Takako Kawasaki; Gregory J Kirkner; Taiki Yamaji; Massimo Loda; Charles S Fuchs
Journal:  Mod Pathol       Date:  2006-11-03       Impact factor: 7.842

Review 8.  Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.

Authors:  James C Cusack
Journal:  Cancer Treat Rev       Date:  2003-05       Impact factor: 12.111

9.  Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma.

Authors:  Ma'anit Shapira; Ofer Ben-Izhak; Bishara Bishara; Boris Futerman; Ira Minkov; Michael M Krausz; Michele Pagano; Dan D Hershko
Journal:  Cancer       Date:  2004-04-15       Impact factor: 6.860

10.  TGFbeta prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest.

Authors:  Jon Lecanda; Vidya Ganapathy; Christine D'Aquino-Ardalan; Brad Evans; Caprice Cadacio; Aidee Ayala; Leslie I Gold
Journal:  Cell Cycle       Date:  2009-03-16       Impact factor: 4.534

View more
  4 in total

1.  Functional comparison between genes dysregulated in ulcerative colitis and colorectal carcinoma.

Authors:  Wenyuan Zhao; Lishuang Qi; Yao Qin; Hongwei Wang; Beibei Chen; Ruiping Wang; Yunyan Gu; Chunyang Liu; Chenguang Wang; Zheng Guo
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

2.  Clinicopathological Characterization and Prognostic Implication of SMAD4 Expression in Colorectal Carcinoma.

Authors:  Seung-Yeon Yoo; Ji-Ae Lee; Yunjoo Shin; Nam-Yun Cho; Jeong Mo Bae; Gyeong Hoon Kang
Journal:  J Pathol Transl Med       Date:  2019-06-24

3.  Genomic adaptations to chemosymbiosis in the deep-sea seep-dwelling tubeworm Lamellibrachia luymesi.

Authors:  Yuanning Li; Michael G Tassia; Damien S Waits; Viktoria E Bogantes; Kyle T David; Kenneth M Halanych
Journal:  BMC Biol       Date:  2019-11-18       Impact factor: 7.431

Review 4.  Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer.

Authors:  Run-Long Lin; Lu-Jun Zhao
Journal:  Cancer Biol Med       Date:  2015-12       Impact factor: 4.248

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.